Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genomic Valley BiotechBOM:539206 +1.07%58 Return-on-Tangible-Asset is 1.37% as of Jun. 2026, which is 121% above its 10-year median of 0.62. GuruFocus rates BOM:539206 with a GF Score™ of 58/100 and a GF Value™ of ₹11.22 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,412 Biotechnology companies, Genomic Valley Biotech ranks better than 80.45% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Genomic Valley Biotech's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹0.58 Mil. Genomic Valley Biotech's average total tangible assets for the quarter that ended in Jun. 2026 was ₹42.50 Mil. Therefore, Genomic Valley Biotech's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 1.37%.
The historical rank and industry rank for Genomic Valley Biotech's Return-on-Tangible-Asset or its related term are showing as below:
BOM:539206'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -7.17 Med: 0.62 Max: 15.79
Current: 0.47
During the past 12 years, Genomic Valley Biotech's highest Return-on-Tangible-Asset was 15.79%. The lowest was -7.17%. And the median was 0.62%.
BOM:539206's Return-on-Tangible-Asset is ranked better than 80.45% of 1412
companies
in the Biotechnology industry
Industry Median: -35.71
vs BOM:539206: 0.47
Genomic Valley Biotech (BOM:539206) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Genomic Valley Biotech Return-on-Tangible-Asset Related Terms
Genomic Valley Biotech Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Genomic Valley Biotech's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomic Valley Biotech Return-on-Tangible-Asset Chart
BOM:539206 vs VRTX, REGN, MRNA: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Genomic Valley Biotech's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomic Valley Biotech Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genomic Valley Biotech's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Genomic Valley Biotech's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 1.37% mean?
Genomic Valley Biotech (BOM:539206) has a Return-on-Tangible-Asset of 1.37% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Genomic Valley Biotech and its competitors. This is 121% above median its historical median of 0.62. According to the industry distribution chart, Genomic Valley Biotech ranks #276 out of 1412 companies in the Biotechnology industry, placing it in the top 19.5%.
Is Genomic Valley Biotech's Return-on-Tangible-Asset too high?
Genomic Valley Biotech's current Return-on-Tangible-Asset of 1.37% is 121% above median its 10-year median of 0.62. Based on the distribution chart, Genomic Valley Biotech ranks #276 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genomic Valley Biotech has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genomic Valley Biotech's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genomic Valley Biotech ranks #276 out of 1412 companies for Return-on-Tangible-Asset. This places Genomic Valley Biotech in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Genomic Valley Biotech and its competitors. Genomic Valley Biotech's current Return-on-Tangible-Asset is 1.37%, which is 121% above median its own 10-year median of 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomic Valley Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genomic Valley Biotech (BOM:539206) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹11.22, compared to a current price of ₹30.20 — trading 169.2% above its estimated fair value. The current Return-on-Tangible-Asset is 1.37%, which is 121% above median its 10-year median of 0.62. Genomic Valley Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Genomic Valley Biotech (BOM:539206), the current Return-on-Tangible-Asset is 1.37% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomic Valley Biotech (BOM:539206) Overvalued in 2026?
Based on GuruFocus' analysis, Genomic Valley Biotech stock appears to be overvalued.
The current stock price of ₹30.20 is trading 169.2% above its estimated GF Value™ of ₹11.22.
GuruFocus considers Genomic Valley Biotech to be Significantly Overvalued.
Key valuation signals for BOM:539206:
Return-on-Tangible-Asset: 1.37% (121% above median its 10-year median of 0.62)
GF Value™: ₹11.22 vs. price of ₹30.20 (169.2% above fair value)
No single metric tells the full story. See the BOM:539206 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomic Valley Biotech Ltd is an India-based biotechnology company operating in the fields of genomics, molecular diagnostics, and AI-driven healthcare. The Company provides Next-Generation Sequencing (NGS) based diagnostic services, oncology diagnostics, personalized healthcare solutions, genetic disease risk assessment, community genomic screening, and research process outsourcing services. Its business is mainly segmented into diagnostic services and research services, with a focus on genomics, bioinformatics, and AI-enabled data analysis. The Company operates mainly in India, while also serving international researchers and collaborators.
58GF Score
Get the complete analysis for BOM:539206
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539206 has been successfully added to your 
